Clinical trial
A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT02169180 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2014
- Completion date
- December 31, 2016
- Enrollment
- 16 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.